AVI BioPharma, Inc. (AVII) Reports Solid Q4 Results; Guides FY12

AVI BioPharma, Inc. (NASDAQ: AVII) reported Q4 EPS of ($0.01), $0.05 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $13.6 million versus the consensus estimate of $11.03 million.

Sees FY2012 revenue of $40-$50 million, versus the consensus of $54.14 million. Sees a loss from operations of $30-$35 million.

For earnings history and earnings-related data on AVI BioPharma, Inc. (AVII) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Optimum Communications gets NYSE non-compliance notice over stock price
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49